Zamyšlení nad osudem konzultativní psychiatrie v ČR

MUDr. Tamara Tošnerová

Psychiatr. pro Praxi, 2005; 5: 215  

SECOND GENERATION ANTIPSYCHOTICS IN THE TREATMENT OF BIPOLAR DISORDER

MUDr. Ivan Tůma CSc

Psychiatr. pro Praxi, 2005; 5: 220-224  

The second generation antipsychotics have expanded the treatment armamentarium for bipolar disorder. Most of the second generation antipsychotic drugs have been found to be effective in clinical controlled trials as monotherapy in bipolar mania or as an add-on treatment with mood stabilizers. The second generation antipsychotic drugs possess a number of advantages, including significantly less extrapyramidal symptoms, diminished risk of tardive dyskinesia, lack of increase in serum prolactin levels (with the exception of risperidone), and improvement in cognition. Data indicate that second generation antipsychotics can serve as adjunctive as well as...

MULTIPLE SCLEROSIS AND DEPRESSION

Eva Havrdová, MUDr. Zdena Čechová

Psychiatr. pro Praxi, 2005; 5: 226-228  

Multiple sclerosis (MS) is a multifocal autoimmune disorder of CNS, characterized besides neurological signs also by both cognitive and affective dysfunction. In old text-books, MS is joined with euphoria which is nearly no more seen in clinical practice. On the contrary, at least 50% of MS patients experience depression during the course of their disease. Depression is very often underdiagnosed and undertreated. Part of the pathophysiology of depression in MS is the inflammation itself. Despite of this, depression in MS patients is very well treatable with modern antidepressants. The treatment of depression substantially improves the quality of life...

COGNITIVE DISORDERS IN OLD AGE

MUDr. Jiří Konrád

Psychiatr. pro Praxi, 2005; 5: 229-232  

The term “cognitive disorders in old age” (inaccurately, in practice often “disorders of memory”) is in the literature described by endless number of syndromes and units. Classification of mainly mild cognitive disorders, which do not fulfil criteria for a dementia and which accompany “normal” aging, is not homogenous and is chaotic. From the historical point of view, we can start with so called “benign senescent forgetfulness” (V. J. Kral 1962), then continue by so called “mild cognitive disorder” and end up with many forms of dementia. In this article, I would like to outline present view...

PHARMACOTHERAPEUTIC OPTIONS IN DEPRESSION

prof. MUDr. Eva Češková CSc

Psychiatr. pro Praxi, 2005; 5: 233-236  

The importance of antidepressants for the further development of psychiatry is summarized. In more details 2 groups of antidepressants, e.g. specific antidepressant influencing preferentially serotonin or norepinephrine/dopamine and dual antidepressants are discussed. New indication within depressive disorder – targeted treatment of depression according to prevalence of symptoms, residual symptoms and breakthrough of pharmacoresistance are discussed. Because the specific antidepressants are well tolerated and safe, the indications are widened also outside the range of depressive disorders.

METABOLIC SYNDROME IN PSYCHIATRY

doc. MUDr. Vladimír Pidrman Ph.D, doc. MUDr. Jiří Horáček CSc

Psychiatr. pro Praxi, 2005; 5: 237-240  

The authors show the risk of obesity as a principal risk of metabolic syndrome explain definition of metabolic syndrome and describe its consequences. They describe risks of metabolic syndrome in psychiatry. They underline connections between metabolic and psychiatry disorders as well as the role of antipsychotic medications in the development of metabolic disorders.

NEW SYNTHETIC DRUGS

MUDr. Tomáš Páleníček

Psychiatr. pro Praxi, 2005; 5: 241-245  

The drug scene is developing similarly as any other scene. According to this fact new problems that have to be solved are arising. One of the most prominent problems of the 21st century is increasing frequency of the use of new synthetic drugs. This phenomenon is closely linked to the widespread use of designer drug ecstasy (3,4-methylendioxymethamphetamine, MDMA). New synthetic drugs are most often associated to the population of ecstasy users, often distributed as to be the ecstasy itself or something similar to it. Phenylethylamine, tryptamine and piperazine derivatives most likely belong to this category. In general, these are drugs acting predominantly...

Tardivní dyskineze vyvolaná atypickými antipsychotiky u rizikových skupin pacientů

MUDr. Klára Látalová

Psychiatr. pro Praxi, 2005; 5: 246-251  

Jak ovlivňuje léčba antipsychotiky morfologii mozku?

MUDr. Martin Anders Ph.D

Psychiatr. pro Praxi, 2005; 5: 252-253  

Použití moklobemidu v preventivní léčbě migrény s aurou

MUDr. Taťjana Majorová

Psychiatr. pro Praxi, 2005; 5: 254-257  

Potřebujeme ještě klasická neuroleptika?

MUDr. Josef Chval

Psychiatr. pro Praxi, 2005; 5: 258  

Rizika při léčbě lithiem

MUDr. Petr Augustin

Psychiatr. pro Praxi, 2005; 5: 259-261